Change the keyword or sentiment above, then click Apply.
Friday, 11 Sep 20262 updates
↗ AI sentiment: Bullish
49% confidence
Senores Pharma's Vadodara Unit Clears USFDA Inspection with Minor Observation
Senores Pharma's subsidiary in Vadodara passed USFDA inspection with one minor procedural observation.
No GMP-related issues were noted; the company will respond within the stipulated timeframe.
Source: BSE
↔ AI sentiment: Neutral
74% confidence
Senores Pharmaceuticals: Co Finishes USFDA Inspection At Subsidiary Apnar Pharma; One Small Procedural Note, No Issues With GMP.
Thursday, 03 Sep 20261 update
↗ AI sentiment: Bullish
92% confidence
Senores Pharma FY26 Revenue Surges 62% to ₹663 Cr, AGM on Sep 25
Senores Pharmaceuticals Ltd. announced its 9th AGM on Sep 25, 2026, via video conferencing, with e-voting from Sep 22-24.
For FY 2025-26, revenue grew 62% to ₹663 Cr, driven by regulated markets and portfolio expansion to 51 ANDAs.
Source: BSE
Wednesday, 26 Aug 20263 updates
↔ AI sentiment: Neutral
88% confidence
Senores Pharma Names New Directors, Approves ESOS 2026
Senores Pharma appoints new Company Secretary & Independent Director on Aug 26, 2026.
Approved ESOS 2026 with 472,000 shares; plans subsidiaries in Mexico & Canada.
Source: ScoutQuest
↔ AI sentiment: Neutral
88% confidence
Senores Pharmaceuticals: Plans to Set Up Operations in Mexico and Canada
↔ AI sentiment: Neutral
71% confidence
Senores Pharma Expands: Subsidiaries in Mexico & Canada
Senores Pharma's board approved a wholly owned subsidiary in Mexico.
The company will also establish a 51% owned subsidiary in Canada.
Source: ScoutQuest
Monday, 24 Aug 20261 update
↔ AI sentiment: Neutral
65% confidence
Senores Pharma Backs ₹62 Cr Loan for Apnar Pharma
Senores Pharma issued a corporate guarantee of INR 62 Cr for Apnar Pharma's credit facility.
The guarantee secures ICICI Bank's loan, recorded as a contingent liability.
Source: ScoutQuest